Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$798K Buy
2,343
+1,516
+183% +$494K 0.02% 194
2026
Q1
$270K Sell
827
-297
-26% -$95.3K 0.01% 295
2025
Q4
$351K Buy
1,124
+301
+37% +$88K 0.01% 254
2025
Q3
$232K Sell
823
-503
-38% -$138K 0.01% 282
2025
Q2
$384K Buy
1,326
+498
+60% +$143K 0.01% 230
2025
Q1
$250K Sell
828
-25
-3% -$6.95K 0.01% 259
2024
Q4
$236K Buy
+853
New +$242K 0.01% 261
2024
Q2
Sell
-1,047
Closed -$271K 291
2024
Q1
$271K Buy
1,047
+70
+7% +$17.2K 0.01% 262
2023
Q4
$221K Buy
+977
New +$214K 0.01% 280
2019
Q3
Sell
-1,807
Closed -$264K 214
2019
Q2
$264K Hold
1,807
0.02% 195
2019
Q1
$254K Sell
1,807
-698
-28% -$92.8K 0.02% 201
2018
Q4
$324K Buy
2,505
+403
+19% +$52.1K 0.02% 177
2018
Q3
$281K Sell
2,102
-49
-2% -$6.63K 0.02% 199
2018
Q2
$273K Buy
+2,151
New +$286K 0.02% 212

Other funds holding CB

Aspiriant LLC's CB Position: Q2 2026 in Review

Aspiriant LLC increased its Chubb (CB) stake by 183% in Q2 2026, buying an estimated $494K and bringing the position to 2,343 shares worth $798K. The position accounts for 0.02% of the portfolio, ranked #194.

Aspiriant LLC first reported a position in CB in Q2 2018 and has held it in 14 quarters since. 408 funds tracked by Wall St. Rank hold CB as of Q2 2026.

  • Aspiriant LLC held 2,343 shares of Chubb worth $798K as of Q2 2026.
  • Aspiriant LLC bought 1,516 Chubb shares in Q2 2026, an estimated $494K.
  • Chubb made up 0.02% of Aspiriant LLC's portfolio in Q2 2026, its #194 holding.
  • Aspiriant LLC first reported a position in Chubb in Q2 2018 and has held it in 14 quarters since.
  • 408 funds tracked by Wall St. Rank held Chubb as of Q2 2026.

Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.